Case ID: M10-179L

Published: 2023-04-14 10:36:07

Last Updated: 1681917272


Michael Sierks
Srinath Kasturirangan

Technology categories

Life Science (All LS Techs)Neurodegenerative Disease TechnologiesNon-Cancer TherapeuticsPharmaceuticals

Technology keywords


Licensing Contacts

Jovan Heusser
Director of Licensing and Business Development
[email protected]

Immunization with amyloid-beta oligomers

Neurodegenerative diseases such as Alzheimer’s Disease (AD) are affecting an increasing number of people, with annual new diagnoses approaching one-half million; and total cost, $150 billion. Early treatment is important for optimal outcomes, but to date, there is no effective treatment on the market for AD. Active immunization for AD is one promising therapeutic approach, yet current techniques utilize monomeric or fibrillar aggregates of the protein beta-amyloid (Aß), rather than the preferred oligomeric Aß form. 


Researchers at Arizona State University have developed a novel therapeutic to treat Alzheimer’s disease in its early, asymptomatic stage, when such treatments are likely to be most effective. Specifically, they have isolated antibody based reagents which catalyze formation of oligomeric Aß species. These antibody reagents, when incubated with monomeric Aß, catalyze formation of large amounts of pure SDS stable oligomeric Aß aggregates in vitro. These pure oligomeric aggregate Aß species can then be used for active immunization to initiate formation of antibodies to the toxic Aß species and not against other Aß forms. This has been demonstrated in vivo with a trans-genic mouse model and in vitro with extracted human brain tissue.


Active immunization, utilizing oligomeric Aß aggregates, presents a novel approach to AD treatment which has real potential to provide a therapeutic benefit at physiologic (non-toxic) doses.

Potential Applications

  • Alzheimer’s Disease treatment


Benefits and Advantages

  • Safety – Immunization against specific oligomeric Aß species, present in very low concentrations, so the inflammatory response in the brain is minimized
  • Creation of large amounts of pure oligomeric Aß, similar to those isolated from brain tissue


For more information about the inventor(s) and their research, please see
Dr. Sierks’ directory webpage
Dr. Sierks’ laboratory webpage